Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation. (FUSION iENA)
I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Martin Freesmeyer, Dr.med.
- Phone Number: +49 3641 9-329805
- Email: martin.freesmeyer@med.uni-jena.de
Study Contact Backup
- Name: Christian Hollenbach
- Phone Number: +49 3641 9-329805
- Email: christian.hollenbach@med.uni-jena.de
Study Locations
-
-
Thuringia
-
Jena, Thuringia, Germany, 07747
- Recruiting
- University Hospital Jena
-
Contact:
- Martin Freesmeyer, Dr.med.
- Phone Number: +49 3641 9-329805
- Email: martin.freesmeyer@med.uni-jena.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with thyroidal nodules,
- euthyroidism
- Uptake >0,5% on Tc-99m-pertechnetate- scintigraphy
Exclusion Criteria:
- thyroid medications in the last 6 months
- Iodine exposition in the last 6 months
- thyroid surgery or radioiodine therapy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Regular Thyroid Work-up
Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics.
Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
|
|
|
Regular Thyroid Work-up and I-124 PET/US
Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study).
Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
|
Assessment of preacquired I-124 PET/US by review of anonymous digital case files
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Metabolic-sonographic nodule allocation
Time Frame: 1 year
|
The number of correct assignments of metabolic function of each nodule will be assessed for each group seperately.
A three-point scale will be used for evaluation of the nodule's function and the degree of the physicians certainty will be investigated using a four-point scale.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- I-124-04/2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Diseases
-
NCT04124705CompletedHypothyroidism | Thyroid Disease | Euthyroid | Thyroid Gland | Thyroid Hormones
-
NCT07124065Active, not recruitingThyroid Cancer | Nodule Solitary Thyroid
-
NCT05377736Active, not recruitingThyroid Cancer | Thyroid Nodule (Diagnosis)
-
NCT05132478CompletedThyroid Cancer | Thyroid Nodule | Benign Thyroid Nodule
-
NCT07296575Active, not recruitingThyroid | Thyroid Cancer | Thyroid Abnormalities
-
NCT03392402CompletedThyroid Cancer | Thyroid Nodule | Thyroid Neoplasm
-
NCT04666103RecruitingThyroid Carcinoma | Thyroid Nodule (Benign) | Ablation; Retina
-
NCT00095693TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid Cancer
-
NCT06225765RecruitingBenign Thyroid Nodule | Suspicious Malignant Thyroid Nodule
-
NCT06283368CompletedThyroid Diseases | Thyroid Cancer | Thyroid Nodule | Thyroid Neoplasms Benign
Clinical Trials on Assessment of already preacquired I-124 PET/US
-
NCT03993327CompletedMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Colorectal Carcinoma Metastatic in the Liver
-
NCT07621614Not yet recruitingCutaneous Melanoma | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Cutaneous Melanocytic Neoplasm | Cutaneous Spitz Melanocytoma
-
NCT02506153Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous Melanoma
-
NCT06401330RecruitingStage I Mixed Cell Type Kidney Wilms Tumor | Stage II Mixed Cell Type Kidney Wilms Tumor | Stage III Mixed Cell Type Kidney Wilms Tumor | Stage IV Mixed Cell Type Kidney Wilms Tumor
-
NCT02997228Active, not recruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v7
-
NCT05238831WithdrawnAnatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent Breast Carcinoma | Recurrent Prostate Carcinoma